ReviewJugan geon-gang gwa jilbyeong2024
[The Evolution of Diabetes Treatment: Combining Innovative Pharmacological Therapies and Advanced Devices toward Remission].
Review in Jugan geon-gang gwa jilbyeong, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of diabetes is rapidly increasing, with one in six adults in the Republic of Korea being affected. Traditional diabetes management focuses on glycemic control to prevent complications. However, recent advancements emphasize individualized treatment strategies. These involve using drugs with a low risk of hypoglycemia and the potential to prevent various metabolic diseases, aiming for diabetes remission, or selecting medications based on comorbidities, regardless of blood glucose levels. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists not only improve glycemic control but also offer cardiovascular and renal protective effects, making them direct therapeutic options for these conditions. Additionally, early combination therapy, involving medications with different mechanisms of action from those used in the early stages of diabetes, is being increasingly promoted to minimize treatment failure and reduce diabetes-related complications. Innovations in diabetes management devices, including continuous glucose monitoring systems, smart insulin pens, and automated insulin delivery systems, have improved glucose control accuracy and enhanced treatment adherence. For type 1 diabetes, novel therapies, such as once-weekly basal insulin and immunotherapies, have been introduced, with various approaches targeting autoimmune responses currently under investigation. This study explored the impact of these emerging therapeutic agents and management devices on diabetes care and presented future prospects for advancing diabetes remission, based on recent research trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.